中国耐多药结核治疗期间获得性耐药的前瞻性队列研究
该多中心前瞻性观察队列纳入2013至2016年286例耐多药结核患者并随访2年,用全基因组测序分析系列分离株。22.0%分离株在治疗期间出现额外耐药,其中65.1%由外源性再感染导致,28.6%为微进化获得性耐药,6.3%为混合感染。既往结核治疗史、广泛肺部病变和2型糖尿病是独立危险因素。
要点
- 耐多药结核治疗期间22.0%分离株出现额外二线耐药,外源性再感染占65.1%。
- 既往结核治疗、广泛肺部病变和2型糖尿病为独立危险因素。
- 提示需加强医疗机构感染控制并重复药敏检测。
核心结论
- 耐多药结核治疗期间出现的额外二线耐药大部分归因于外源性再感染,提示需加强感染控制并重复药敏检测。
研究设计与样本
- 多中心前瞻性观察队列研究纳入2013至2016年286例耐多药结核患者,随访2年至治疗完成,对系列分离株行全基因组测序。
主要发现
- 286例中63例(22.0%)分离株在治疗期间出现额外耐药,其中5例符合广泛耐药结核标准。
- 额外二线耐药中41例(65.1%)由外源性再感染导致,18例(28.6%)由微进化获得性耐药导致,4例(6.3%)由耐药与敏感株混合感染导致。
- 多因素分析显示既往结核治疗(aHR 2.51,95%CI 1.51-4.18)、胸部X线广泛病变(aHR 3.39,95%CI 2.03-5.66)和2型糖尿病(aHR 4.00,95%CI 2.22-7.21)是额外二线耐药的独立危险因素。
临床怎么用
- 对耐多药结核患者应加强医疗机构感染控制以减少外源性再感染。
- 治疗期间需重复进行药敏检测以及时发现额外二线耐药。
- 对既往治疗史、广泛肺部病变或合并2型糖尿病者应加强耐药监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Little is known about how additional second-line drug resistance emerges during multidrug-resistant tuberculosis (MDR-TB) treatment. The present study aimed to investigate the influence of microevolution, exogenous reinfection and mixed infection on second-line drug resistance during the recommended 2-year MDR-TB treatment. METHODS: Individuals with MDR-TB were enrolled between 2013 and 2016 in a multicentre prospective observational cohort study and were followed up for 2 years until treatment completion. Whole-genome sequencing (WGS) was applied for serial Mycobacterium tuberculosis isolates from study participants throughout the treatment, to study the role of microevolution, exogenous reinfection and mixed infection in the development of second-line drug resistance. RESULTS: Of the 286 enrolled patients with MDR-TB, 63 (22.0%) M. tuberculosis isolates developed additional drug resistance during the MDR-TB treatment, including 5 that fulfilled the criteria of extensively drug-resistant TB. By comparing WGS data of serial isolates retrieved from the patients throughout treatment, 41 (65.1%) of the cases of additional second-line drug resistance were the result of exogenous reinfection, 18 (28.6%) were caused by acquired drug resistance, i.e. microevolution, while the remaining 4 (6.3%) were caused by mixed infections with drug-resistant and drug-susceptible strains. In multivariate analysis, previous TB treatment (adjusted hazard ratio (aHR) 2.51, 95% CI 1.51-4.18), extensive disease on chest X-ray (aHR 3.39, 95% CI 2.03-5.66) and type 2 diabetes mellitus (aHR 4.00, 95% CI 2.22-7.21) were independent risk factors associated with the development of additional second-line drug resistance. CONCLUSIONS: A large proportion of additional second-line drug resistance emerging during MDR-TB treatment was attributed to exogenous reinfection, indicating the urgency of infection control in health facilities as well as the need for repeated drug susceptibility testing throughout MDR-TB treatment.
引用
- Hu Y, Zheng X, Davies Forsman L, et al. Emergence of additional drug resistance during treatment of multidrug-resistant tuberculosis in China: a prospective cohort study. Clin Microbiol Infect. 2021. PMID: 33895338. doi:10.1016/j.cmi.2021.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。